KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Liabilities (2016 - 2025)

Teva Pharmaceutical Industries' Total Liabilities history spans 17 years, with the latest figure at $32.8 billion for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 2.3% year-over-year to $32.8 billion, compared with a TTM value of $32.8 billion through Dec 2025, down 2.3%, and an annual FY2025 reading of $32.8 billion, down 2.3% over the prior year.
  • Total Liabilities for Q4 2025 was $32.8 billion at Teva Pharmaceutical Industries, up from $32.6 billion in the prior quarter.
  • The five-year high for Total Liabilities was $38.0 billion in Q1 2021, with the low at $32.1 billion in Q1 2025.
  • Average Total Liabilities over 5 years is $35.1 billion, with a median of $35.3 billion recorded in 2023.
  • Year-over-year, Total Liabilities rose 1.92% in 2024 and then decreased 8.75% in 2025.
  • Tracing TEVA's Total Liabilities over 5 years: stood at $36.4 billion in 2021, then decreased by 2.77% to $35.4 billion in 2022, then decreased by 0.17% to $35.4 billion in 2023, then dropped by 4.94% to $33.6 billion in 2024, then dropped by 2.3% to $32.8 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Total Liabilities are $32.8 billion (Q4 2025), $32.6 billion (Q3 2025), and $33.3 billion (Q2 2025).